Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...

Hims & Hers (HIMS) is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s decision to end compounded ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

Health and wellness platform Hims & Hers Health, Inc. (NYSE:HIMS), which has gained traction for its obesity-related ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

HIMS boasts high gross margins (~80%) with no R&D risk, capitalizing on the shift away from traditional pharmacies to ...

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...

Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Even without the contribution from GLP-1 drugs, revenue growth would have soared. The stock is cheap given the company's revenue growth and margins. Hims & Hers strong performance involves much ...